Read The Latest Posts From Our Newsletter.
Our newsletter tracks recent developments in the biotech industry. We explore genetic medicine, AI in biotech and the examine the breakthrough science that is driving our new, advanced medicines.
Kevin Curran, the Bridgepoint Bio founder, is the author of our newsletter. Visit this link to sign up for Kevin’s substack newsletter.
2105, 2024
How are LNPs used to deliver gene editing tools into the human body?
Crispr/Cas9 is working well...but we're still learning how to move this cargo into specific cells. (2/3)
705, 2024
How can we deliver gene editing tools into the human body?
Crispr/Cas9 is working well...but we're still learning how to move this cargo into the correct cells. (1/3)
1604, 2024
How does the new gene editing drug work?
I present a short video describing how Casgevy works for Sickle Cell Disease
2203, 2024
New gene therapy grabs headlines with a $4.25M price tag, but the science is the real story
Lenmeldy therapy genetically engineers bone marrow cells... these cells then travel to the brain to resolve a genetic disorder